Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Gangat N, et al. Among authors: abdelmagid m. Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564. Online ahead of print. Am J Hematol. 2024. PMID: 39671248
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Gangat N, et al. Among authors: abdelmagid m. Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10. Am J Hematol. 2024. PMID: 38071734
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Elliott MA, Mangaonkar A, Saliba A, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A, Gangat N. Karrar O, et al. Among authors: abdelmagid m. Am J Hematol. 2024 Feb;99(2):E63-E66. doi: 10.1002/ajh.27180. Epub 2023 Dec 15. Am J Hematol. 2024. PMID: 38100217
PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
Tefferi A, Fathima S, Alsugair AKA, Aperna F, Natu A, Abdelmagid MG, Csizmar CM, Gurney M, Lasho TL, Finke CM, Mangaonkar AA, Al-Kali A, Pardanani A, Reichard KK, He R, Gangat N, Patnaik MM. Tefferi A, et al. Among authors: abdelmagid mg. Am J Hematol. 2024 Dec;99(12):2321-2327. doi: 10.1002/ajh.27492. Epub 2024 Sep 27. Am J Hematol. 2024. PMID: 39329442
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Singh A, Al-Kali A, Foran JM, Elliott MA, Begna K, Badar T, Khera N, Fleti F, Abdelmagid M, Reichard KK, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Singh A, et al. Among authors: abdelmagid m. Am J Hematol. 2022 Oct;97(10):E377-E379. doi: 10.1002/ajh.26672. Epub 2022 Aug 12. Am J Hematol. 2022. PMID: 35959963 Free article. No abstract available.
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases.
Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. Fleti F, et al. Among authors: abdelmagid mg. Am J Hematol. 2023 Apr;98(4):E76-E79. doi: 10.1002/ajh.26845. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36655582 Free article. No abstract available.
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Gangat N, et al. Among authors: abdelmagid m. Haematologica. 2024 Jan 1;109(1):187-292. doi: 10.3324/haematol.2023.283732. Haematologica. 2024. PMID: 37534525 Free PMC article. No abstract available.
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Abdelmagid MG, et al. Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x. Blood Cancer J. 2023. PMID: 37567878 Free PMC article.
36 results